Navigation Links
Hill-Rom Announces CEO Succession Plan
Date:9/17/2009

BATESVILLE, Ind., Sept. 17 /PRNewswire-FirstCall/ -- The Board of Directors of Hill-Rom Holdings, Inc. (NYSE: HRC) today announced plans to facilitate the orderly succession and retirement of Peter H. Soderberg, president and CEO. Consistent with his wishes conveyed at the time of his arrival in 2006 and endorsed by the Board at that time, Soderberg will formally retire as an employee of the company at the end of April 2011 (at age 65).

The Board has formed a search committee to identify a new CEO and has retained Spencer Stuart, a leading executive recruiting firm, to advise the Board. The search process, which is already underway, will include a full review of both internal and external candidates. Soderberg will remain as President and CEO until a successor is named, which is anticipated to occur in 2010. After the new CEO assumes responsibility, Soderberg will become Chief Innovation Officer reporting to the new President and CEO. In that role, it is anticipated that Soderberg will continue to advise and help shape the company's business and product innovation initiatives on a part-time basis. Soderberg will remain on the Board until his successor has taken office.

"Hill-Rom is in a strong position as a result of Peter's leadership. We have a clear and focused strategy and continue to execute it successfully in spite of the economic downturn. Consistent with our succession planning process and obligation to shareholders and employees, the Board is committed to an extensive search for the right candidate and expects the transition to be seamless," said Rolf A. Classon, Hill-Rom's Board Chairman and an independent director.

Joanne Smith, as chair of the company's Nominating and Corporate Governance committee, added, "We are in a p
'/>"/>

SOURCE Hill-Rom Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
2. Hill-Rom Announces Singapore Will Be Site for Asia-Pacific Innovation Center
3. Hill-Rom Introduces Fashionable, Affordable Bed for Home and Post-Acute Care Patients
4. Cerner Corporation and Hill-Rom Partner to Unify Hospital Care Delivery
5. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
6. Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill-Rom and Batesville Casket
7. Hill-Rom Holdings, Inc. Announces Completion of Separation of Hillenbrand Industries Creating Two Public Companies
8. Hill-Roms NaviCare(R) WatchChild(R) Solution Provides Enhanced Information Technology Solutions for Obstetrical Care
9. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast
10. Hill-Rom to Present at the Bank of America 2008 Health Care Conference
11. Hill-Rom to Present at the Citi Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Medizone International, Inc. (OTC ... Board of Directors and the Board of Medizone ... Medizone International Inc. holds a 50% interest, agreed ... venture and reconvey to Medizone International all global ... Medizone International,s Chairman, Edwin G. Marshall said, "Time ...
(Date:12/16/2009)... Delaware, December 16 While many ... their accurate forecast models,for new and inmarket ... patient-based forecast solutions to various players. These ... phase II, as well as phase,III. These ... product life cycle,management, market entry strategy, manufacturing ...
(Date:12/16/2009)... access to patient information could improve care, but ... 16 (HealthDay News) -- U.S. physicians support the ... exist about privacy problems, two new studies show. ... practice and specialist doctors in Massachusetts found that ... would improve patient quality of care, 70 percent ...
(Date:12/16/2009)... in triathalons and appeared on The Amazing Race ... to think of herself as part human, part machine. , ... 34-year-old triathlete likes to describe herself. When she,s not training ... school auditoriums or posing nude with her metal leg crossed ... latest ESPN Body Issue. , She is the ...
(Date:12/16/2009)... site visitors can earn a free 21-count one week trial bottle ... ... Orion, MI (PRWEB) December 16, 2009 -- ImmuneResponse247.com ... Trial Sample” of Immune Response 247™ 6 Mushroom Formula , ... Medicinals, Immune Response 247™ 6 Mushroom Formula is packaged in FDA ...
Breaking Medicine News(10 mins):Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pros and Cons of Electronic Medical Records Weighed 2Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4
... vaccine has proved to be efficient on animals according to researchers ... can cure HIV infection. This is our hope," said Dr. Young ... vaccine are expected soon with almost $5i million to be invested ... medical revelation. ,Dr. Yong Kang said, "We have ...
... its treatment by the FDA, following a clinical trial. ... survived an average of 11.4 months without disease progression, ... ,The drug will be used before radiation, in ... squamous cell head and neck cancer. Its side effects ...
... conducted a randomised, placebo controlled, double blind trial on 87 ... popular antiaging// supplement DHEA(dehydroepiandrosterone). The report published in the New ... the findings that DHEA cannot be considered the magic potion ... the drug does not have any marked impact on the ...
... divulged that AIDS is no more restricted to just risk ... cases are added each day according to statistics with almost ... AIDS positive. It is alarming to note that like Africa, ... mode of infection is now common through even heterosexual contact ...
... the effects of the country's worst epidemic of the ... having been infected by Chikungunya,// according to the World ... yesterday by the WHO, over 1.25 million suspected cases ... life-threatening is debilitating with severe joint pain and high ...
... A French study that was stopped abruptly due to safety ... clear the clogged neck arteries, which could result in// stroke ... had proved that stents were indeed a safe bet to ... ,To make a comparative study, researchers used stents and ...
Other Medicine News:Health News:The Search For Eternal Youth-DHEA Not The Magic Potion 2Health News:45% of Indians Affected by Chikungunya Fever 2Health News:Bottleneck for Neck Stents - May Enhance Risk of Stroke, Says a Study 2
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
(Date:12/16/2009)... Dec. 16 Naurex Inc., a new ... and other CNS disorders based on its novel ... presented at a major medical meeting showed that ... anxiolytic-like activity with no signs of the CNS-related ... NMDA receptor(1). The studies also showed that ...
(Date:12/16/2009)... NEW YORK, Dec. 16 Keryx ... today the initiation of a Phase 3 ... Company,s PI3K/Akt pathway inhibitor, in relapsed / ... entitled, "A Phase 3 Randomized Study to ... Added to the Combination of Bortezomib (Velcade®) ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 1New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 2Parents key in new measure to evaluate language in children with autism 48494 1Parents key in new measure to evaluate language in children with autism 48494 2Parents key in new measure to evaluate language in children with autism 48494 3Pre pregnancy depressed mood may heighten risk for premature birth 8792 1Pre pregnancy depressed mood may heighten risk for premature birth 8792 2Pre pregnancy depressed mood may heighten risk for premature birth 8792 3
... ARIAD,Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical,investigators ... and,1b clinical data from ongoing trials of the ... of the American Society,of Clinical Oncology (ASCO) in ... from the Phase 2 trial of single-agent,AP23573 in ...
... /PRNewswire-FirstCall/ -- Iomai,Corporation today announced that it will ... patch-based needle-free influenza vaccine,before the markets open tomorrow. ... at 8:30 a.m. Eastern Time tomorrow to discuss,the ... the live conference call Friday, May 25, 2007 ...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
Medicine Products: